Raymond James Trust’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $1.78M | Sell |
3,829
-232
| -6% | -$111K | 0.04% | 348 |
|
|
2024
Q2 | $1.9M | Sell |
4,061
-142
| -3% | -$61.6K | 0.04% | 324 |
|
|
2024
Q1 | $1.76M | Buy |
4,203
+101
| +2% | +$42.7K | 0.04% | 339 |
|
|
2023
Q4 | $1.67M | Sell |
4,102
-107
| -3% | -$39.5K | 0.04% | 337 |
|
|
2023
Q3 | $1.46M | Buy |
4,209
+25
| +0.6% | +$8.74K | 0.04% | 331 |
|
|
2023
Q2 | $1.47M | Sell |
4,184
-131
| -3% | -$44.1K | 0.04% | 331 |
|
|
2023
Q1 | $1.36M | Sell |
4,315
-58
| -1% | -$17.4K | 0.04% | 343 |
|
|
2022
Q4 | $1.26M | Sell |
4,373
-55
| -1% | -$16.8K | 0.04% | 347 |
|
|
2022
Q3 | $1.28M | Sell |
4,428
-661
| -13% | -$190K | 0.05% | 319 |
|
|
2022
Q2 | $1.43M | Sell |
5,089
-1,143
| -18% | -$306K | 0.05% | 303 |
|
|
2022
Q1 | $1.63M | Buy |
6,232
+401
| +7% | +$95.2K | 0.05% | 301 |
|
|
2021
Q4 | $1.28M | Sell |
5,831
-362
| -6% | -$70.4K | 0.04% | 363 |
|
|
2021
Q3 | $1.12M | Buy |
6,193
+1,133
| +22% | +$221K | 0.04% | 372 |
|
|
2021
Q2 | $1.02M | Sell |
5,060
-220
| -4% | -$46K | 0.03% | 398 |
|
|
2021
Q1 | $1.13M | Buy |
5,280
+486
| +10% | +$107K | 0.04% | 337 |
|
|
2020
Q4 | $1.13M | Buy |
4,794
+348
| +8% | +$79.8K | 0.04% | 326 |
|
|
2020
Q3 | $1.21M | Buy |
4,446
+483
| +12% | +$133K | 0.05% | 276 |
|
|
2020
Q2 | $1.15M | Buy |
3,963
+415
| +12% | +$113K | 0.06% | 275 |
|
|
2020
Q1 | $844K | Sell |
3,548
-497
| -12% | -$114K | 0.05% | 299 |
|
|
2019
Q4 | $886K | Sell |
4,045
-861
| -18% | -$174K | 0.04% | 331 |
|
|
2019
Q3 | $831K | Buy |
4,906
+536
| +12% | +$94.8K | 0.04% | 340 |
|
|
2019
Q2 | $802K | Sell |
4,370
-17
| -0.4% | -$2.97K | 0.04% | 329 |
|
|
2019
Q1 | $807K | Sell |
4,387
-452
| -9% | -$83.5K | 0.05% | 325 |
|
|
2018
Q4 | $802K | Buy |
4,839
+299
| +7% | +$51.8K | 0.05% | 293 |
|
|
2018
Q3 | $875K | Buy |
4,540
+65
| +1% | +$11.6K | 0.05% | 302 |
|
|
2018
Q2 | $761K | Buy |
4,475
+174
| +4% | +$27K | 0.05% | 323 |
|
|
2018
Q1 | $701K | Buy |
4,301
+342
| +9% | +$55.9K | 0.05% | 307 |
|
|
2017
Q4 | $594K | Buy |
3,959
+49
| +1% | +$7.25K | 0.04% | 339 |
|
|
2017
Q3 | $594K | Buy |
3,910
+91
| +2% | +$13.7K | 0.04% | 331 |
|
|
2017
Q2 | $492K | Buy |
3,819
+154
| +4% | +$18.5K | 0.04% | 377 |
|
|
2017
Q1 | $401K | Sell |
3,665
-20
| -0.5% | -$1.76K | 0.03% | 419 |
|
|
2016
Q4 | $272K | Sell |
3,685
-45
| -1% | -$3.66K | 0.02% | 514 |
|
|
2016
Q3 | $325K | Buy |
3,730
+143
| +4% | +$13.5K | 0.03% | 442 |
|
|
2016
Q2 | $308K | Sell |
3,587
-321
| -8% | -$27.7K | 0.03% | 458 |
|
|
2016
Q1 | $311K | Sell |
3,908
-1,589
| -29% | -$144K | 0.03% | 446 |
|
|
2015
Q4 | $692K | Buy |
5,497
+1,667
| +44% | +$201K | 0.06% | 276 |
|
|
2015
Q3 | $399K | Sell |
3,830
-205
| -5% | -$26.3K | 0.04% | 348 |
|
|
2015
Q2 | $498K | Buy |
4,035
+20
| +0.5% | +$2.52K | 0.05% | 316 |
|
|
2015
Q1 | $473K | Sell |
4,015
-619
| -13% | -$74.2K | 0.05% | 335 |
|
|
2014
Q4 | $551K | Buy |
4,634
+317
| +7% | +$35.7K | 0.06% | 301 |
|
|
2014
Q3 | $485K | Buy |
4,317
+382
| +10% | +$36.4K | 0.06% | 309 |
|
|
2014
Q2 | $372K | Buy |
3,935
+98
| +3% | +$6.87K | 0.04% | 375 |
|
|
2014
Q1 | $271K | Buy |
3,837
+679
| +22% | +$53.8K | 0.03% | 438 |
|
|
2013
Q4 | $234K | Buy |
3,158
+289
| +10% | +$20.1K | 0.03% | 476 |
|
|
2013
Q3 | $217K | Sell |
2,869
-298
| -9% | -$23.7K | 0.03% | 479 |
|
|
2013
Q2 | $253K | Buy |
+3,167
| New | +$233K | 0.04% | 381 |
|
Other funds holding VRTX
Raymond James Trust's VRTX Position: Q3 2024 in Review
Raymond James Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 5.7% in Q3 2024, selling an estimated $111K and leaving 3,829 shares worth $1.78M. The position accounts for 0.04% of the portfolio, ranked #348.
Raymond James Trust first reported a position in VRTX in Q2 2013 and has held it in 46 quarters since. The position peaked at $1.9M in Q2 2024. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.
- Raymond James Trust held 3,829 shares of Vertex Pharmaceuticals worth $1.78M as of Q3 2024.
- Raymond James Trust sold 232 Vertex Pharmaceuticals shares in Q3 2024, an estimated $111K.
- Vertex Pharmaceuticals made up 0.04% of Raymond James Trust's portfolio in Q3 2024, its #348 holding.
- Raymond James Trust first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
- Raymond James Trust's Vertex Pharmaceuticals position peaked at $1.9M in Q2 2024.
- 1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.
Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.